Immunome Inc. financial data

Symbol
IMNM on Nasdaq
Location
Bothell, WA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 03 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1185% % 83%
Debt-to-equity 10% % -48%
Return On Equity -58% % 54%
Return On Assets -52% % 50%
Operating Margin -3229% % 4.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 113,133,199 shares 30%
Common Stock, Shares, Outstanding 113,133,199 shares 76%
Entity Public Float $728,500,000 USD 13%
Common Stock, Value, Issued $11,000 USD 83%
Weighted Average Number of Shares Outstanding, Basic 87,350,956 shares 49%
Weighted Average Number of Shares Outstanding, Diluted 87,350,956 shares 49%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $6,941,000 USD -23%
Research and Development Expense $177,286,000 USD 37%
General and Administrative Expense $43,768,000 USD 33%
Operating Income (Loss) $224,113,000 USD 27%
Net Income (Loss) Attributable to Parent $212,394,000 USD 28%
Earnings Per Share, Basic -2.43 USD/shares 51%
Earnings Per Share, Diluted -2.43 USD/shares 51%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $653,482,000 USD 356%
Assets, Current $660,777,000 USD 199%
Property, Plant and Equipment, Net $14,636,000 USD 45%
Operating Lease, Right-of-Use Asset $2,978,000 USD -30%
Other Assets, Noncurrent $4,587,000 USD 4%
Assets $683,188,000 USD 184%
Accounts Payable, Current $3,339,000 USD -76%
Employee-related Liabilities, Current $11,527,000 USD 97%
Contract with Customer, Liability, Current $0 USD -100%
Liabilities, Current $44,990,000 USD -17%
Contract with Customer, Liability, Noncurrent $2,208,000 USD -77%
Deferred Income Tax Liabilities, Net $801,000 USD -22%
Operating Lease, Liability, Noncurrent $3,855,000 USD -19%
Liabilities $48,845,000 USD -17%
Accumulated Other Comprehensive Income (Loss), Net of Tax $0 USD -100%
Retained Earnings (Accumulated Deficit) $728,164,000 USD -41%
Stockholders' Equity Attributable to Parent $634,343,000 USD 250%
Liabilities and Equity $683,188,000 USD 184%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $53,055,000 USD -375%
Net Cash Provided by (Used in) Financing Activities $162,228,000 USD -26%
Net Cash Provided by (Used in) Investing Activities $5,089,000 USD
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 113,133,199 shares 76%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $114,262,000 USD -33%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $653,692,000 USD 356%
Deferred Tax Assets, Valuation Allowance $152,318,000 USD 43%
Deferred Tax Assets, Gross $153,119,000 USD 42%
Operating Lease, Liability $3,855,000 USD -20%
Payments to Acquire Property, Plant, and Equipment $3,665,000 USD 69%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $212,451,000 USD 27%
Lessee, Operating Lease, Liability, to be Paid $16,930,000 USD 33%
Operating Lease, Liability, Current $0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,330,000 USD 79%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,468,000 USD 58%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $3,737,000 USD -11%
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,383,000 USD 51%
Deferred Tax Assets, Operating Loss Carryforwards $62,577,000 USD 113%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $56,000 USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $2,437,000 USD 51%
Additional Paid in Capital $1,362,496,000 USD 96%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $611,000 USD 289%
Deferred Tax Assets, Net of Valuation Allowance $801,000 USD -22%
Share-based Payment Arrangement, Expense $25,690,000 USD 63%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%